Honokiol
Honokiol inhibits STAT3/NF-κB (prolif/inflam ↓), elevates ROS (mito stress), triggers apoptosis (caspase/Bcl-2), + PI3K/mTOR/VEGF suppression. Preclinical robust in breast/lung/CRC/ovarian/prostate; 100–500 mg PO safe but limited human data—monitor CYP/GI.
Forms: Oral capsules/extracts (supplement, 100–400 mg)
Key Takeaway
Magnolia bark compound that turns off STAT3/NF-κB growth switches, raises ROS to stress tumors, and pushes cells into apoptosis; promising in lab models, early human data limited.
Evidence at a glance
Strong preclinical (in vitro/in vivo); human limited to phase I safety/PK; oncology trials pending.
How it may work
Honokiol, a lignan from magnolia bark, inhibits STAT3 and NF-κB signaling, reducing inflammation-driven tumor growth and metastasis. It induces reactive oxygen species (ROS)-mediated apoptosis by disrupting mitochondrial function, upregulating caspases, and downregulating anti-apoptotic proteins like Bcl-2. Honokiol also suppresses PI3K/Akt/mTOR pathways, limiting cell proliferation, and inhibits angiogenesis via VEGF downregulation. Preclinical studies show efficacy in breast, lung, and colorectal cancer models, with potential to overcome drug resistance.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
- STAT3↓p-STAT3 (Tyr705) inhibition; reduces proliferation/metastasis
- NF-κB↓p65 translocation ↓; curbs inflammation
- ROS↑Mitochondrial disruption; precedes apoptosis
- Apoptosis↑Caspase ↑, Bcl-2 ↓; intrinsic pathway
- PI3K/Akt/mTOR↓Limits proliferation; VEGF ↓ for anti-angiogenesis
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Rapamycin: Apoptosis enhancement in breast.
- Curcumin: NF-κB/ROS in lung.
- Resveratrol: STAT3 suppression in CRC.
Overlapping mechanisms
- STAT3 ↓ / NF-κB ↓ / ROS ↑ / Apoptosis ↑: Caution stacking with other STAT3/NF-κB/ROS/apoptotics; risk GI/CYP without added value.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
Timing
- With meals: Reduces GI upset; enhances absorption.
- Divided BID: Steady levels; e.g., 200 mg AM/PM.
References
- PMC7016989
- DOI 10.1016/j.cbi.2023.110725
- DOI 10.21873/anticanres.13877
- DOI 10.1016/j.ejphar.2008.09.057
Research
No published studies for Honokiol yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 100–500 mg (po) Supplements: 100–400 mg/day divided. Preclinical HED from mouse (5–20 mg/kg) ~0.4–1.6 mg/kg (~28–112 mg for 70 kg); human pilots/exploratory: 200–500 mg/day. No established oncology dose., From magnolia bark extract standardized to honokiol. Divided BID with meals. Bioavailability low; liposomal forms emerging. Monitor GI; not Rx—quality varies..
Trials studying Honokiol
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →